Since ancient times plant and animal tissues have been used as medicines. In the 20th century growth hormone as a purified extraction from human pituitaries was still used to treat growth disorders. Since the genetic engineering of host cells became possible, a new generation of medicines obtained using recombinant DNA (rDNA) technology has emerged. These medicines have been named 'biopharmaceuticals'. The first biopharmaceutical growth hormones were patented in the 1980s, so already over two decades of clinical experience support the development of a new, off-patent growth hormone preparation obtained by rDNA technology. The European Medicines Agency (EMEA) has put in place a centralised procedure for the approval of new biopharmaceuticals. This procedure includes testing comparability with a reference product and demands post-approval pharmacovigilance. Omnitrope ® was the first off-patent recombinant human growth hormone (rhGH) approved on the basis of the biosimilar pathway; it underwent a very demanding approval procedure in 2006 and is now used for several indications in Europe, the US, Canada, Japan, Australia and other countries where it has received marketing approval.
Biologics
Biological medicines have been used since ancient times and are plant-derived. Healing plants were grown next to the temples of the ancient Egyptians and herbs to which therapeutic properties are attributed are still cultivated today. Phytotherapy still plays a considerable role in healthcare, although the safety and efficacy of applied herbal medicine procedures have not been proved using modern methods from evidence-based medicine. Animal tissue extracts are still used as biological medicine. More than 100 years ago it was found that pituitary extracts affect growth. Maurice Raben first isolated pituitary human growth hormone (pit-hGH) from human pituitaries collected at autopsy (1951) and used it in GHdeficient patients (1958) . Soon afterwards, a period of therapeutic use of pituitary-derived hGH, which has lasted for more than 20 years, began.
In the late 1970s, after many years of scientific research into DNA technology, the techniques of cutting at specific sites and replicating and synthesising DNA molecules greatly improved, and inserting specific DNA into bacterial or mammalian cells became possible. The host cell replicates inserted DNA in a natural way and synthesises the protein coded by the DNA. From that time on, it was possible to obtain active components of complex high-molecular-weight molecules for medical purposes.
Continuous development of analytical methods and biological assays improved biotechnology methods, and thus an increasing number of complex molecules could be produced. Industrial manufacturing started in the early 1980s by cultivating genetically modified micro-organisms or cells, which was followed by purification of an active ingredient. Soon several important new drugs were patented; drugs obtained using this technique were called 'biopharmaceuticals' (see Figure 1 ). Insulin and GH were the first human hormones to be produced this way.
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Biopharmaceuticals
The first biopharmaceuticals were soon introduced to the market without specifically designed regulatory procedures for approval.
However, after >20 years of their use for various indications, there is extensive clinical experience and their safety and efficacy profile is well known.
In 2001, the first patents protecting biopharmaceuticals expired.
Over a period of several years and in keeping with technology development, the European Drug Agency (EMEA) developed a new legislation regulatory pathway for off-patent biopharmaceuticals.
The procedures used for the approval of generics did not protect adequately against possible pitfalls in the sophisticated production and purification of biopharmaceuticals. The difference between generics and off-patent biopharmaceuticals is shown in Table 1 . 'similar biological medicinal products' or 'biosimilars'. In the opinion of the author of this article, the name is misleading. There is no common understanding (and cannot be) that 'biosimilar' describes a regulatory pathway and is a regulatory term, and it does not mean that this new product is a different, yet similar, medicine. The first approved biosimilar medicinal product was approved more than three years ago. It was the rhGH Omnitrope ® and there is still a lot of misunderstanding concerning the drug among doctors and patients. To avoid confusion, the wording should be more similar to that used in the US, which is clearer - 
Biopharmaceutical Growth Hormone
The Reference Product
The revolutionary new technology of recombinant DNA (rDNA) has come just in time, as the supply of insulin obtained from animal sources was barely sufficient to meet the demands of the rapidly growing global population of patients with diabetes. However, the story of GH was more dramatic. In 1985, >25 years after the first patient had received pit-hGH, four young adult patients developed Creutzfeldt-Jakob disease. All of these patients had been receiving pithGH for many years. After intensive investigation, it became obvious that the pituitary glands used for the extraction of GH administered to these patients were most probably collected from individuals with Creutzfeldt-Jakob disease and were contaminated with slow viruses. 2 The first production of GH with the use of genetically modified Escherichia coli by Genentech Inc. was reported in 1977. In the critical year of 1985, almost 100 children in clinical trials received DNA recombinant methionyl GH (rhGH), 3, 4 
Recombinant DNA BiotechnologyBenefits and Hazards
The insertion of DNA encoding for the desired protein, e.g. hGH, into the host cell genome, either directly or using a plasmid as a vehicle,
Pituitary Disorders 
Figure 1: Biopharmaceuticals -A New Era of Biologics
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Omnitrope
Omnitrope is the first off-patent biopharmaceutical to receive market approval according to EMEA centralised procedures.
Regulatory criteria for approval were designed to prove comparability with a reference product, Genotropin, which is Omnitrope with the reference product and to assess its long-term safety and efficacy. To meet this aim, a population of 89 children with idiopathic GH deficiency diagnosed in accordance to the worldwide accepted criteria were randomised to Omnitrope group A (n=44) or Genotropin group B (n=45). The patients were GH-naïve.
In the study, a lyophilised Omnitrope formulation was used, as the reference product was of the same formulation. The study comparing Omnitrope with the reference product was carried out for nine months; the first six months is the period of treatment with the most intense growth response to GH -the so-called catch-up period. Moreover, selected GHD-naïve pre-pubertal children were the population most sensitive to GH. A study planned in this way is considered to be the best model to detect any differences between GH preparations. Randomised groups were similar for all auxological parameters before the treatment was started. There were no significant statistical differences between the groups in any of the time-points assessed during the treatment period (three, six and nine months of the treatment; see Figures 2 and 3 ). Adverse reactions observed in patients did not differ between the groups.
To assess the long-term safety and efficacy of both formulations of Omnitrope -the lyophilised and the more convenient ready-to-use liquid formulation -the study of the same group of patients was continued for up to seven years. 9, 10 Results showed that in terms of safety profile and efficacy, Omnitrope was therapeutically similar to Genotropin and, according to the data from literature, to other preparations of rhGH such as Saizen and Norditropin.
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Conclusion
The process of developing Omnitrope was planned to fulfil the rigorous demands of the EMEA centralised registration procedure.
It has created an opportunity to excel in the production of high-quality biopharmaceuticals.
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